+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global DNA Vaccine Market Research and Forecast, 2022-2028

  • Report

  • 110 Pages
  • July 2022
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 4537378

Global DNA Vaccine Market Size, Share & Trends Analysis Report By Type (Animal DNA Vaccine and Human DNA Vaccine), By Technology (Plasmid DNA Vaccines Technology and Plasmid DNA Delivery Technology), By Application (Oncology, Infectious Diseases, and Others) Forecast, 2022-2028

The global DNA vaccines market is growing at a considerable CAGR of around 7.6% during the forecast period (2022-2028). The factors that drive the growth of the market include the increasing number of various antibiotics resistant pathogens and the increasing population with infectious diseases that have created the need for low-cost and efficacious vaccines that would deliver immunity for a long period. The DNA vaccines are also effective against infectious diseases in animals and have successfully eliminated key animal pathogens. DNA vaccines come with numerous advantages such as the low risk of infection as compared to conventional vaccines, easy transference, and constancy at room temperature. Additionally, rapid development in the field of molecular biology, immunology, and DNA synthesis contributing to the growth of the market. Along with that, the inefficient drug therapies and rising microbial resistance to existing ‘antimicrobials and antibiotics’ treatments providing ample opportunity to increase the DNA vaccine market during the forecast period.

Impact of COVID-19 on the Global DNA Vaccines Market

The COVID-19 pandemic has a positive impact on the global DNA vaccines market since December 2019. The market is increasing due to the development of vaccines as the globe deals to find a cure for the disease. The major market players are focusing on the ongoing clinical trials of nucleic acid vaccines against COVID-19 with the use of DNA technology. For instance, In April 2020. INOVIO Pharmaceuticals, the US-based biotech company announced that the company is in phase I clinical trial to protect against Covid-19. The characteristic of the vaccine is DNA plasmid encoding S protein delivered by electroporation. Additionally, In June 2021, The company expands its partnership with Advaccine Biopharmaceuticals Suzhou Co., Ltd. to conduct a global Phase 2/3 efficiency trial of the COVID-19 DNA vaccine.

Segmental Outlook

The market is segmented based on type, technology, application. Based on type, the market is segmented into animal DNA vaccine and human DNA vaccine. Based on technology, the market is segmented into plasmid DNA vaccines technology and plasmid DNA delivery technology. On the basis of application, the market is segmented into oncology, infectious diseases, and others.

Global DNA Vaccines Market Share by Type, 2020 (%)

Global DNA Vaccines Market Share by Type

The Animal Vaccine segment is projected to grow significantly in the global DNA Vaccine market

Among types, The animal DNA vaccine segment is estimated to grow significantly in the global animal vaccine market during the forecast period. The segment is increasing due to the increasing availability of DNA Vaccines for animal diseases that includes West Nile Innovator (Horse), Apex-IHN (Salmon fish), canine melanoma vaccine (DOG), and Life tide-SW5 (Swine and other food animals). Hence, the rising prevalence of these diseases creates an opportunity for animal DNA vaccine manufacturers. Additionally, the DNA vaccine is more effective and less expensive as compared to other vaccines. DNA vaccines are suitable for mass vaccination, and. DNA vaccines have been prospective solutions for poultry diseases. DNA vaccines can be used for immediate jabs in contradiction of multiple pathogens and are comparatively easy to design and inexpensive to manufacture and store.

Regional Outlooks

The global DNA vaccines market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America developed as a profitable market for DNA vaccines market. The market is increasing in North America due to the initiatives by the regional government to immunize citizens, along with the prevalence of the aids of genetic vaccines targeted towards animals. For instance, In May 2021, GC Pharma announced that the US Food and Drug Administration (FDA) accepted the company’s Biologics License Application (BLA) for 'GC5107 (Immune Globulin Intravenous (Human),10% Liquid)’ anticipated for the treatment of Primary Humoral Immunodeficiency (PI), which is a type of congenital genetic disorders that causes an individual to have a lacking or absent immune system.

Global DNA Vaccines Market, by Region 2022-2028

Global DNA Vaccines Market, by Region

Asia-Pacific will Have Considerable Growth in the Global DNA Vaccines market

Asia-Pacific is estimated to have considerable growth in the global DNA vaccine market during the forecast period. The market is increasing in this region due to the rising government initiatives, and increasing prevalence of people regarding the benefits of vaccination against Human papillomavirus (HPV) and Hepatitis B. are some factors that drive the growth of the market in the Asia-Pacific.

Market Player Outlook

Key players of the global DNA vaccines market include Pfizer Inc., Merck & Co., Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., INOVIO Pharmaceuticals., General Electric Co., GlaxoSmithKline plc., Hoffmann-La Roche Ltd, Bharat Biotech International Ltd., GC Pharma corp., and others. To sustain a significant position in the market, these players adopt different marketing strategies such as product launches. For instance, in 2018, Astellas Pharma Inc entered into a global partnership worldwide (excluding China), with Juventas Therapeutics, the agreement was for option, and license agreement for Juventas’ lead product candidate, JVS-100. JVS-100. It is a non-viral gene therapy that expresses stromal cell-derived factor-1 (SDF-1).

The Report Covers

  • Market value data analysis of 2020 and forecast to 2027.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global DNA vaccines market based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where in the market

Table of Contents

1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global DNA Vaccine Industry
  • Recovery Scenario of Global DNA Vaccine Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global DNA Vaccine Market by Type
5.1.1. Animal DNA Vaccine
5.1.2. Human DNA Vaccine
5.2. Global DNA Vaccine Market by Technology
5.2.1. Plasmid DNA Vaccines Technology
5.2.2. Plasmid DNA Delivery Technology
5.3. Global DNA Vaccine Market by Application
5.3.1. Oncology
5.3.2. Infectious Diseases
5.3.3. Others
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Arbutus Biopharma
7.2. Astellas Pharma Inc.
7.3. Bayhill Therapeutics
7.4. Bharat Biotech International Ltd.
7.5. Dendreon Pharmaceuticals LLC.
7.6. GC Pharma Corp.
7.7. General Electric Co.
7.8. GlaxoSmithKline plc.
7.9. Hoffmann-La Roche Ltd
7.10. Indian Immunologicals Ltd.
7.11. INOVIO Pharmaceuticals.
7.12. Merck & Co., Inc.,
7.13. Pfizer Inc.
7.14. QED Bioscience Inc.
7.15. Sanofi S.A.
7.16. Serum Institute of India Pvt. Ltd.
7.17. Xenetic Biosciences, Inc.
7.18. Zoetis Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Arbutus Biopharma
  • Astellas Pharma Inc.
  • Bayhill Therapeutics
  • Bharat Biotech International Ltd.
  • Dendreon Pharmaceuticals LLC.
  • GC Pharma Corp.
  • General Electric Co.
  • GlaxoSmithKline plc.
  • Hoffmann-La Roche Ltd
  • Indian Immunologicals Ltd.
  • INOVIO Pharmaceuticals.
  • Merck & Co., Inc.,
  • Pfizer Inc.
  • QED Bioscience Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Xenetic Biosciences, Inc.
  • Zoetis Inc.